亿诺药业

Biotech/Healthcare

Eno Pharmaceuticals develops cardiovascular therapies. The company is currently focused on developing a potential first-in-class small-molecule inhibitor targeting the innate immune system to treat reperfusion injury following acute myocardial infarction.

Latest round: Pre Series A (2023)